Semaglutide and tirzepatide are prescription medications and should only be used under the supervision of a licensed medical provider
For 503A pharmacies, FDA reiterated a limited enforcement policy from its 2018 guidance, Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: the agency does not intend to take action where a compounder fills four or fewer prescriptions per calendar month of a drug that is essentially a copy of a commercially available drug
Its approval in the United States and China, as well as its fast track and priority review status, highlight its potential to address critical medical conditions.
These products are not approved for human consumption, medical use, therapeutic applications, or diagnostic procedures
Few peptides have gained as much attention as BPC-157 , a naturally derived compound known for its remarkable ability to accelerate healing, reduce inflammation, and protect the gut lining